| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
41,560,000 |
| Market
Cap: |
257.67(M) |
| Last
Volume: |
5,200 |
Avg
Vol: |
5,186 |
| 52
Week Range: |
$3.61 - $10.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
118,082 |
130,582 |
180,030 |
368,410 |
| Total Sell Value |
$980,899 |
$1,074,708 |
$1,509,387 |
$3,484,755 |
| Total People Sold |
5 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
7 |
9 |
21 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-12-15 |
4 |
D |
$16.50 |
$72,155 |
D/D |
(4,373) |
61,683 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-12-15 |
4 |
OE |
$4.81 |
$72,150 |
D/D |
15,000 |
66,056 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2020-12-03 |
4 |
OE |
$3.67 |
$14,703 |
D/D |
3,812 |
8,614 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-11-09 |
4 |
AS |
$15.00 |
$264,255 |
D/D |
(17,617) |
26,029 |
|
46% |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-11-09 |
4 |
AS |
$14.53 |
$203,420 |
D/D |
(14,000) |
644,869 |
|
46% |
|
| Gold Mark Stephen |
Director |
– • – |
2020-11-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
15,596 |
296,266 |
|
- |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2020-10-30 |
4 |
AS |
$12.41 |
$939,353 |
D/D |
(75,683) |
5,000 |
|
63% |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2020-10-30 |
4 |
OE |
$5.04 |
$302,400 |
D/D |
60,000 |
80,683 |
|
- |
|
| Freitag Gregory Gene |
Director |
– • – |
2020-09-15 |
4 |
OE |
$3.67 |
$47,879 |
D/D |
13,046 |
244,530 |
|
- |
|
| Blackford Quentin S. |
Director |
– • – |
2020-09-03 |
4 |
A |
$11.75 |
$30,444 |
D/D |
2,591 |
18,126 |
|
- |
|
| Wendell Amy Mcbride |
Director |
– • – |
2020-09-03 |
4 |
A |
$11.75 |
$30,444 |
D/D |
2,591 |
25,924 |
|
- |
|
| Neels Guido J |
Director |
– • – |
2020-09-03 |
4 |
A |
$11.75 |
$30,444 |
D/D |
2,591 |
2,591 |
|
- |
|
| Rudelius Robert James |
Director |
– • – |
2020-09-03 |
4 |
A |
$11.75 |
$30,444 |
D/D |
2,591 |
48,183 |
|
- |
|
| Levine Alan M |
Director |
– • – |
2020-09-03 |
4 |
A |
$11.75 |
$30,444 |
D/D |
2,591 |
2,591 |
|
- |
|
| Gold Mark Stephen |
Director |
– • – |
2020-09-03 |
4 |
A |
$11.75 |
$30,444 |
D/D |
2,591 |
311,862 |
|
- |
|
| Gold Mark Stephen |
Director |
– • – |
2020-08-12 |
4 |
GD |
$0.00 |
$0 |
I/I |
17,500 |
309,271 |
|
- |
|
| Freitag Gregory Gene |
General Counsel |
• • – |
2020-05-29 |
4 |
OE |
$3.50 |
$437,500 |
D/D |
125,000 |
231,484 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-05-28 |
4 |
OE |
$3.67 |
$62,400 |
D/D |
15,000 |
43,646 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-04-28 |
4 |
OE |
$0.27 |
$683 |
D/D |
2,530 |
51,056 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-04-16 |
4 |
OE |
$4.81 |
$55,916 |
D/D |
11,625 |
658,869 |
|
- |
|
| Scopelianos Angelo |
VP Research & Development |
• – – |
2020-02-18 |
4 |
D |
$14.68 |
$5,784 |
D/D |
(394) |
2,249 |
|
- |
|
| Scopelianos Angelo |
VP Research & Development |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,326 |
2,643 |
|
- |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2020-02-18 |
4 |
D |
$14.68 |
$47,798 |
D/D |
(3,256) |
20,683 |
|
- |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
10,811 |
21,529 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,605 |
28,646 |
|
- |
|
529 Records found
|
|
Page 12 of 22 |
|
|
0.11 (1.81%) 
